I feel ENTA stock is severely mispriced after the sell-off last week. The data in treatment-experienced patients was excellent. Considering the 100M in cash on the balance sheet, no debt, and the forfeited 195M milestone payment upon approval, a 200% premium over the company's existing valuation would not be out of the question.